Vtv therapeutics inc. (VTVT)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss before noncontrolling interest

-7,165

-6,882

-5,960

-5,114

-3,982

-2,328

-1,961

-9,596

-9,960

-14,592

-12,355

-13,414

-14,286

-13,711

-13,505

-14,617

-13,520

-11,059

-9,823

-10,412

-9,813

Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:
Gain on disposal of property and equipment, net

-

-

-

-

-

0

0

0

12

0

16

0

-5

-

-

-

-

-

-

-

-

Depreciation expense

27

15

8

8

8

107

30

39

42

45

48

52

52

49

68

69

79

140

114

114

133

Share-based compensation expense

380

423

413

401

281

331

579

803

963

988

959

959

739

653

682

699

607

-

-

-

-

Change in fair value of contingent distribution

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,405

-710

Change in fair value of warrants, related party

363

223

146

-275

-921

1,248

-319

-316

25

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt discount

47

82

115

150

185

219

248

272

275

276

274

276

203

-

-

-

-

-

-

-

-

Non-cash interest expense distribution payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

13

14

Bad debt (recovery) expense related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

-232

0

230

Changes in assets and liabilities:
Accounts receivable

-

-

-

-

-

0

-2,270

2,060

-7,790

-

-

-

-

0

0

-206

137

-

-

-

50

Prepaid expenses and other assets

-465

-73

619

59

-1,337

-340

-445

-152

2,072

-283

86

-143

170

-446

635

-923

232

315

642

-100

163

Employee loans receivable – related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

-21

0

-25

0

-11

0

-1

Receivable due from a related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

230

Long-term deposits

-

-

-

-

-

0

0

0

-2,256

-

-

282

37

-

-

-

-

-

-

-

-

Other long-term assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

-3

264

-

-15

-2

1,611

Accounts payable and accrued expenses

331

170

-1,423

2,080

-1,445

-1,263

-4,179

1,848

-2,605

3,741

-614

-371

-308

1,369

554

1,535

1,328

1,386

-922

-444

2,910

Accounts payable and accrued expenses – related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-406

94

-310

-258

364

235

1,125

734

Contract liabilities

-8

-7

-8

-827

-913

-4,523

-3,375

-473

-2,064

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,086

24

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-17

-

0

-76

-122

-

-

-

-

Other liabilities

-

-

-

-

-

0

2

1

-35

5

12

4

3

10

0

17

-8

141

-82

-143

-787

Net cash used in operating activities

-5,560

-5,876

-6,195

-5,497

-5,450

-5,869

-6,260

-9,330

-5,397

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-13,816

-

-12,728

-11,553

-12,502

-8,970

-9,822

-8,788

-9,366

Proceeds from sale of assets

-

-

-

-

-

0

0

0

12

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

18

0

0

39

-

-

-

-

62

9

29

4

Net cash provided by (used in) investing activities

-

-

-

-

-

0

-5

0

12

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from issuance of Class A Common Stock to a related party under the Letter Agreements

6,000

8,000

9,000

4,500

6,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of Class A Common Stock, net of offering costs

-

0

0

0

5,443

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-39

-

-

-

-

-37

-9

-29

-4

Proceeds from debt issuance

-

-

-

-

-

-

-

-

-

-

0

0

7,500

-

-

-

-

-

-

-

-

Repayment of notes payable

1,811

2,715

2,641

2,500

2,717

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

4,189

5,285

6,859

2,000

8,726

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents

-1,371

-659

974

-3,497

3,276

-2,083

2,603

-5,372

-5,385

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from debt issuance related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

13

10,476

8,800

Repayment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-38

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

7,500

-

-

-

-

0

104,444

10,438

8,762

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-6,355

-

-12,783

-11,660

-12,502

-9,007

94,613

1,621

-608

Non-cash activities:
Change in redemption value of noncontrolling interest

-14,454

-5,398

-2,560

5,814

15,549

-43,807

18,336

74,460

3,884

-

-

-

-

-

-

-

-

-

-

-

-

Exchange of vTv Therapeutics Inc. Class B Common Stock and vTv Therapeutics, LLC member units for vTv Therapeutics Inc. Class A Common Stock

-

-

-

-

-

0

0

0

151

-

-

-

-

0

19

1,933

1,212

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,073

295

Deferred revenue included in accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

550

Redeemable Noncontrolling Interest [Member]
Change in redemption value of noncontrolling interest

14,454

5,398

2,560

-5,814

-15,549

43,807

-18,336

-74,460

-3,884

-

-

-

-

-

-

-

-

-

-

-

-